Kestra Advisory Services’s Protagonist Therapeutics PTGX Stock Holding History

Kestra Advisory Services’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$620K	Buy	5,061 +7	+0.1%	+$731	﹤0.01%	2175
2026 Q1	$533K	Sell	5,054 -88	-2%	-$7.79K	﹤0.01%	2171
2025 Q4	$449K	Sell	5,142 -81	-2%	-$6.63K	﹤0.01%	2238
2025 Q3	$347K	Sell	5,223 -540	-9%	-$30.7K	﹤0.01%	2325
2025 Q2	$319K	Buy	5,763 +582	+11%	+$27.9K	﹤0.01%	2298
2025 Q1	$251K	Sell	5,181 -466	-8%	-$19.5K	﹤0.01%	2309
2024 Q4	$218K	Buy	5,647 +464	+9%	+$20.2K	﹤0.01%	2434
2024 Q3	$233K	Buy	+5,183	New	+$209K	﹤0.01%	2263
2022 Q1	–	Sell	-7,833	Closed	-$268K	–	2099
2021 Q4	$268K	Buy	+7,833	New	+$248K	﹤0.01%	1672
2021 Q3	–	Sell	-13,939	Closed	-$626K	–	2164
2021 Q2	$626K	Buy	13,939 +310	+2%	+$10.2K	0.01%	1163
2021 Q1	$353K	Buy	+13,629	New	+$345K	﹤0.01%	1365

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Kestra Advisory Services's PTGX Position: Q2 2026 in Review

Kestra Advisory Services increased its Protagonist Therapeutics (PTGX) stake by 0.14% in Q2 2026, buying an estimated $731 and bringing the position to 5,061 shares worth $620K. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Kestra Advisory Services first reported a position in PTGX in Q1 2021 and has held it in 11 quarters since. The position peaked at $626K in Q2 2021. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Kestra Advisory Services held 5,061 shares of Protagonist Therapeutics worth $620K as of Q2 2026.
Kestra Advisory Services bought 7 Protagonist Therapeutics shares in Q2 2026, an estimated $731.
Protagonist Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #2175 holding.
Kestra Advisory Services first reported a position in Protagonist Therapeutics in Q1 2021 and has held it in 11 quarters since.
Kestra Advisory Services's Protagonist Therapeutics position peaked at $626K in Q2 2021.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.